The maintenance of genome stability during mitosis is coordinated by the spindle assembly checkpoint (SAC) through its effector the mitotic checkpoint complex (MCC), an inhibitor of the anaphasepromoting complex (APC/C, also known as the cyclosome) 1,2 . Unattached kinetochores control MCC assembly by catalysing a change in the topology of the β-sheet of MAD2 (an MCC subunit), thereby generating the active closed MAD2 (C-MAD2) conformer [3][4][5] . Disassembly of free MCC, which is required for SAC inactivation and chromosome segregation, is an ATP-dependent process driven by the AAA+ ATPase TRIP13. In combination with p31 . Here, we present a mechanism that explains how TRIP13-p31 comet disassembles the MCC. Cryo-electron microscopy structures of the TRIP13-p31 comet -C-MAD2-CDC20 complex reveal that p31 comet recruits C-MAD2 to a defined site on the TRIP13 hexameric ring, positioning the N terminus of C-MAD2 (MAD2   NT   ) to insert into the axial pore of TRIP13 and distorting the TRIP13 ring to initiate remodelling. Molecular modelling suggests that by gripping MAD2
. Our study provides insights into how specific substrates are recruited to AAA+ ATPases through adaptor proteins and suggests a model of how translocation through the axial pore of AAA+ ATPases is coupled to protein remodelling.
To investigate disassembly of the MCC catalysed by the joint action of p31 comet and TRIP13, we incubated p31 comet and TRIP13 with ATP and either free MCC or MCC in complex with the APC/C (APC/C-MCC). comet and the APC/C mediating independent SAC silencing pathways 8, 9, [11] [12] [13] [14] [15] [16] . The TRIP13 catalytic mutant (TRIP13(E253Q)) 17 is defective in generating O-MAD2 (Extended Data Fig. 1a (lanes 3, 4, 9, 10), b). When incubated with the MCC and p31 comet , a TRIP13(E253Q) hexamer formed a complex with p31 comet , CDC20 and MAD2 in a 1:1:1:1 stoichiometry, consistent with previous findings 7, 18 (Extended Data Fig. 1c ). p31 comet , but not TRIP13, interacts with the free MCC and APC/C-MCC (Extended Data Fig. 1b, d ). The substrate of the TRIP13 ATPase reaction is the p31 comet -C-MAD2-CDC20 complex (referred to hereafter as p31-substrate), which forms a tight complex with TRIP13(E253Q) (Extended Data Fig. 1e ).
We then determined the cryo-EM structure of the TRIP13(E253Q)-p31-substrate complex with ATPγS (Extended Data Fig. 1e) . Refinement of the electron microscopy data set yielded a 3D reconstruction at 4.5 Å resolution, extending to 4.3 Å for focused refinement of TRIP13 monomers A-D (Extended Data Fig. 3 , Extended Data Table 1 ). 3D classification revealed three structural classes (Extended Data Fig. 4 ). Class 1 is the unliganded apo TRIP13 hexamer, and classes 2 and 3 belong to two distinct conformational states of the TRIP13(E253Q)-p31-substrate complex. TRIP13 in class 2 represents the basal state, whereas class 3 presents structural rearrangements in TRIP13, suggestive of an activated state. An atomic model for apo TRIP13 was built into the overall electron microscopy density map, guided by the crystal structure of a TRIP13 monomer 18 (Fig. 1a , Extended Data Fig. 4a , Extended Data Table 1 ). In the cryo-electron microscopy (cryo-EM) structure, TRIP13 forms a closed hexameric ring featuring a central pore, whereas in the crystal structure adjacent subunits assemble into a helical filament 18 ( Fig. 1a , Extended Data Fig. 5a ). The TRIP13 cryo-EM structure also differs from the flat closed ring of the Caenorhabditis elegans TRIP13 orthologue PCH2 17 (Fig. 1a , Extended Data Fig. 5a ).
Our cryo-EM structure shows that with ATPγS the TRIP13 ring adopts a compact conformation with a convex top surface and concave lower surface (Fig. 1a, Extended Data Fig. 5a ). Monomers A-E form a right-handed spiral. Monomer F, which is structurally distinct from its counterparts owing to the separation of its large and small AAA+ domains (although less pronounced than that of the open subunits of PCH2
17
; Extended Data Fig. 5b ), forms a seam in the hexameric ring that bridges monomers A and E (Fig. 1a, Extended Data Fig. 5a, b) . Clear cryo-EM density is visible for ATPγS at monomers A-E (Extended Data Fig. 3e ). Pore loop-1, which occludes the central pore in the PCH2 flat ring conformation, rotates upwards (Extended Data Fig. 5c ) such that Trp221 and Phe222 of monomer A are exposed on the surface.
To build the basal state TRIP13(E253Q)-p31-substrate model (class 2 of the 3D classification; Extended Data Fig. 4c ), the crystal structure of the p31 comet -C-MAD2 dimer 19 was docked into the large cryo-EM density feature above the convex face of TRIP13 (Fig. 1b, Extended  Data Fig. 3c, d ). The p31 comet -C-MAD2 dimer undergoes little conformational change except for a structural rearrangement of MAD2 NT (Extended Data Fig. 6a, b) . The conformation of the TRIP13 ring is essentially identical to that of apo TRIP13 (Extended Data Fig. 4b ). The main contact between p31-substrate and TRIP13 involves a conserved basic surface on p31 comet opposite the C-MAD2 interface (Figs. 1b, 2a , b and Supplementary Video 1). Strikingly, p31 comet positions C-MAD2 so that MAD2 NT , which extends from the start of the αA helix, is precisely located to enter the TRIP13 pore (Figs. 1b, 3a , Extended Data Fig. 3d, f) . Notably, structural elements of C-MAD2 that are remodelled on conversion to O-MAD2-the β8′-β8′′ hairpin and safety belt (Extended Data Fig. 6b, c) 18, 20 . Combined deletion of seven basic residues of the α3-4 loop severely ablated TRIP13-catalysed modelling of MAD2, without disrupting complex assembly (Fig. 2c,  Extended Data Figs. 2c, 7d ).
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In the TRIP13-p31-substrate complex, C-MAD2 interacts tightly with p31 comet through the MAD2 dimerization interface 19,21-23 and entraps the MAD2-binding motif (MBM) of CDC20 under its safety belt (Fig. 1b) . No other density for CDC20 was visible (Extended Data Fig. 3c, d ). As previously reported 18 , the 109-117 loop of C-MAD2 interacts with pore loop-1 of TRIP monomer A. MAD2
NT adopts a fully extended conformation with residues 2-9 inserting mid-way into the narrow pore at the centre of TRIP13 (Figs. 1b, 3a , Extended Data Fig. 3d , f and Supplementary Video 1). In this configuration, the conserved TRIP13 pore loop-1 Trp221 and Phe222 of monomers B-D embrace residues 2-7 of MAD2 NT (Fig. 3a, Extended Data Fig. 3f ). Trp221 and Phe222 are responsible for MAD2 processing 17 . Pore loop-1 of monomer E is too low in the TRIP13 spiral to contact MAD2 NT ( Fig. 3a) , whereas that of monomer F is disordered.
Monomer A of TRIP13 also interacts with MAD2 NT through the underlying acidic pore loop-2 (Fig. 3a) , contributing a key specificity determinant for MAD2 NT . The region of MAD2
NT that forms intimate contacts with conserved pore loop residues of monomers A-D is hydrophobic and basic (L 3 QLSR 7 ) (Fig. 3a) . Although the cryo-EM density for side chains of MAD2
NT and pore loops-2 is incomplete, it is indicative of interactions between Arg7 of MAD2 NT and Glu269 and Asp272 of pore loop-2 of monomer A, with Leu3 and Leu5 of MAD2 NT contacting the Phe222 side chains of pore loops-1 of monomers C and B, respectively.
Notably, the MAD2 NT L 3 QLSR 7 motif is conserved in MAD2 homologues and other TRIP13 HORMA-domain protein substrates 18 (Extended Data Fig. 8c ). To test the importance of the MAD2
NT LSR sequence, we compared the efficacy of O-MAD2 release from a C-MAD2-CDC20 complex incorporating either wild-type C-MAD2 or a mutant in which LSR was replaced by LEE. Release of O-MAD2 was reduced in the LEE mutant ( NT is important for TRIP13 function. A TRIP13 mutant in which Glu269 and Asp272 were replaced with either Ala or Arg was completely defective in MAD2 remodelling (Fig. 3c, Extended Data Fig. 2c) . Removal of the first seven residues of MAD2 severely impaired O-MAD2 release (Fig. 3b (lanes  3-6) , Extended Data Fig. 2b ), but deleting up to nine residues from the MAD2 N terminus did not affect complex assembly (Extended Data Fig. 7d ). These findings agree with a previous study, in which deletion of the first five residues of MAD2 (ΔN5-MAD2) abolished both the ability of TRIP13 to convert C-MAD2 to O-MAD2, and the substrate-dependent stimulation of TRIP13 ATPase activity 18 . . To explore how TRIP13 ATPase activity induces conformational changes in C-MAD2, we modelled the likely structure of the TRIP13-p31-substrate complex after the first cycle of catalysis ( . Owing to these steric clashes, the globular portion of p31-substrate moves vertically relative to MAD2
NT held within the TRIP13 pore by subunits A 1 to D 1 (Extended Data Fig. 9a, d ). An anticlockwise rotation of the globular portion of p31-substrate allows p31 comet to engage the reset TRIP13 interface 60° anticlockwise. Were the entire p31-substrate (including MAD2 NT ) to shift, the Leu13 Cα atom (the start of αA of C-MAD2) would be displaced by 7.6 Å after the first catalytic step (Extended Data Fig. 9i ). However, because MAD2
NT is gripped by the TRIP13 pore, fixing Leu13 Cα, the αA helix unwinds to stretch the polypeptide chain (Extended Data Fig. 9f-j) . Modelling indicates that each round of catalysis causes a single α-helical turn to unwind into an extended conformation, coupled with progression of MAD2
NT through the TRIP13 pore by two residues ( Unwinding the αA helix suggests that the conversion of C-MAD2 to O-MAD2 occurs through disruption of contacts with the adjacent β8′-β8′′ hairpin, including hydrogen bonds linking Ser16 of αA with Thr188 and His191 of β8′-β8′′ (Fig. 4c, d , Supplementary Video 2). As these hydrogen bonds stabilize C-MAD2 18, 25 , their loss would displace β8′-β8′′. Opening the buckle (β8′-β8′′ pairing with β5) releases the safety belt structure that traps CDC20 to C-MAD2, liberating CDC20 (Extended Data Fig. 6d ). Restructuring of β8′-β8′′and the C-MAD2 C terminus weakens interactions with p31
comet that bind C-MAD2 , the conformational transition of C-MAD2 would involve unwinding of no more than the αA helix.
p31-substrate stimulates TRIP13 ATPase activity 17 , indicating that it promotes an activating conformational change of TRIP13. NT residues interacting with TRIP13 pore loop residues. b, Western blot showing input (i) and O-MAD2 fractions of the disassembly of the CDC20-C-MAD2 complex by TRIP13(E253Q) (lanes 1, 2) and wildtype TRIP13 (lanes 3-8). MAD2 levels and loading controls for TRIP13 and CDC20 were detected using their respective antibodies. Mutants of MAD2 NT (lanes 5-8) affect the amount of O-MAD2 released from the CDC20-C-MAD2 complex. c, Mutation of D269 and E272 of pore loop-2 of TRIP13 ablates TRIP13-p31 comet -catalysed remodelling of MAD2 (Extended Data Fig. 2c ). Experiments in b, c were performed in triplicate with similar results. 
The conformational differences in the TRIP13-p31-substrate complex between classes 2 and 3 suggest that class 3 is an activated state primed for ATP hydrolysis. Compared with class 2, TRIP13 monomers D-F have changed their orientations relative to monomers A-C, with the conformational change progressively increasing from D to F and resulting in their shift towards p31-substrate (Fig. 5a , Supplementary Video 4). These changes in TRIP13 are accompanied by a small rotation of p31 comet -C-MAD2 so that p31 comet itself moves closer to TRIP13 monomers D and E. Monomer F shows the largest displacement towards the p31-substrate module, allowing its pore loop-2 to approach MAD2 NT (Fig. 5a,b) . The effect of the p31-substrate-induced conformational change in TRIP13 is to move monomers E and F along the axis of translocation.
On conversion of O-MAD2 to C-MAD2 the β2-β3 hairpin rearranges. Mutations of the β2-β3 hairpin suppress this conversion 27 .
In the activated state, the approaching F monomer shifts the β2-β3 hairpin towards αA, perturbing its interactions with the C-MAD2 core (Fig. 5b ). Thus, it is possible that the energy of p31-substrate binding to TRIP13 is converted into torsional energy within the TRIP13 ring that destabilizes C-MAD2 core interactions with the β2-β3 hairpin.
The proposed TRIP13-catalysed rotary motion of the globular region of p31 comet -C-MAD2 relative to the fixed MAD2
NT presents a mechanism to explain how local unwinding of a secondary structural element remodels tertiary and quaternary structures (Fig. 5c ).
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MEthodS
Cloning, expression and purification of TRIP13 complexes. The codonoptimized DNA coding sequences (CDSs) of full-length human TRIP13 (Q15645) and p31 comet (also known as MAD2L1BP; Q15013) were cloned individually into the bacterial pETM11 expression vector with an N-terminal TEV protease-cleavable His 6 tag. MAD2 (also known as MAD2L1; Q13257) CDS was cloned into a custom-modified version of the pETM11 vector where the N-terminal His 6 tag was replaced by a C-terminal 3C-cleavable His 6 tag. TRIP13 and p31 comet mutants were generated using QuickChange and MAD2 mutants were generated using Gibson cloning. These include TRIP13: E269A plus D272A and E269R plus D272R, E253Q; MAD2: L5S6R7 to L5E6E7; and the N-terminal 7 and 9 residue deletions; p31 comet : deletion of R99, K100, K110, K111, K112, R122, K123 and K270A (TRIP13-binding site on monomer E). Proteins were individually expressed in the BL21 Star (DE3) Escherichia coli strain at 18 °C for 12 h. TRIP13, p31 comet and MAD2 were individually purified by Ni-NTA based protein purification (Ni-NTA agarose resin) followed by either TEV or 3C protease cleavage and gel filtration (Superdex 75 10/300 column). TRIP13 and p31 comet were further purified on a 6-ml Resource Q column (GE Healthcare Life Sciences) before size exclusion chromatography. Cloning, expression and purification of MCC and the APC/C-MCC complex were as described 28 .
C-MAD2 complex remodelling experiments. Purified p31
comet and either wildtype or mutant MAD2 were incubated with purified maltose-binding protein (MBP)-CDC20 (Q13257) 28 for 2 h at 23 °C. The resulting p31 comet -C-MAD2-MBP-CDC20 complex was purified by gel filtration using a Superdex 200 10/300 column. For disassembly of either the p31 comet -C-MAD2-MBP-CDC20 complex or the MCC (both the MCC alone and MCC in the APC/C-MCC complex), 10-15 μmol of complex was incubated with a threefold molar excess of TRIP13 (either wild-type or the Q253E mutant, accounting for hexamerization of TRIP13), in a disassembly buffer (50 mM HEPES pH 8.0, 10 mM MgCl 2 and 3 mM ATP) in a total volume of 50 μl. In the reactions containing MCC and APC/C-MCC, a tenfold excess of p31 comet was also added. Following incubation at 23 °C for 10 min the disassembly reaction was injected into a ÄKTAmicro (GE Healthcare) with a running buffer of 20 mM HEPES pH 8.0, 300 mM NaCl, 10 mM MgCl 2 and 0.5 mM TCEP. O-MAD2 eluted in a later fraction than the complexes of C-MAD2 either with p31 comet or with both p31 comet and MBP-CDC20 (Extended Data Fig. 2a) . O-MAD2 fractions were loaded (with input material) onto an SDS-PAGE gel and detected with a western blot using anti-MAD2 antibody (ab10691; Abcam). TRIP13, CDC20 and p31 comet were detected with antibodies against TRIP13 (sc-514285; Santa Cruz Biotechnology), CDC20 (sc-8358; Santa Cruz Biotechnology) and p31 comet (MABE451; Merck), respectively. To test dissociation of MCC into C-MAD2-CDC20 and BUBR1-BUB3 (BUBR1: O60566; BUB3:O43684) sub-complexes by (i) the combined action of TRIP13(E253Q) and p31 comet , (ii) TRIP13(E253Q) alone and (iii) p31 comet alone, 30 μmol MCC was mixed with (i) a 1.1-fold excess of TRIP13(E253Q) hexamer and a tenfold excess of p31 comet , (ii) a 1.1-fold excess of TRIP13(E253Q) or (iii) a tenfold excess of p31 comet in buffer: 50 mM HEPES pH 8.0, 10 mM MgCl 2 and 3 mM ATP. The mixture was injected into a Superdex 200 10/300 gel filtration column fitted to an ÄKTAmicro (GE Healthcare) with a running buffer of 20 mM HEPES pH 8.0, 300 mM NaCl, 10 mM MgCl 2 and 0.5 mM TCEP and ATP. Peak eluted fractions were analysed using Coomassie-stained gels. Reconstitution of TRIP13-p31-substrate complex for EM analysis. A ternary complex composed of p31 comet -C-MAD2-CDC20 was purified by Ni-NTA column chromatography starting with a co-lysate of Hi-5 insect cells 28 co-expressing C-MAD2-MBP-CDC20 with BL21 Star (DE3) cells expressing p31 comet , followed by TEV cleavage and gel filtration (Superdex 200 10/300 column). Purified TRIP13(Q253E) was incubated with equimolar amounts of the p31 comet -C-MAD2-CDC20 complex (accounting for hexamerization of TRIP13) in an assembly reaction buffer (50 mM HEPES pH 8.0, 10 mM MgCl 2 and 5 mM ATPγS) for 45 min at 23 °C. The 50-μl assembly reaction was injected into a Superdex 200 5/150 GL column fitted to an ÄKTAmicro (GE Healthcare) with a running buffer containing 20 mM HEPES pH 8.0, 300 mM NaCl, 10 mM MgCl 2 , 0.5 mM TCEP and 0.3 mM ATPγS. The complex eluted in a peak fraction at a concentration of 0.3 mg/ml and was used to prepare cryo-EM grids. Electron microscopy. We applied 2.5 μl of the TRIP13-p31-substrate complex eluted fraction to Quantifoil Holey carbon R1.2/1.3 Au 300 grids, treated with a 9:1 argon:oxygen plasma for 30 s before use. The grids were incubated for 30 s at 4 °C and 100% humidity and then blotted for 6 s and plunged into liquid ethane using an FEI Vitrobot III. Specimens were imaged using both EPU software (FEI) and Serial EM (Mastronarde Group) at a nominal magnification of 81,000×, yielding a pixel size of 1.43 Å at specimen level on an FEI Titan Krios electron microscope operating at 300 kV accelerating voltage. Zero-energy-loss micrographs were recorded using a Gatan K2-Summit direct electron detector executed in counting mode at the end of a Gatan GIF-Quantum energy filter with a slit width of 20 eV. Images were collected at a dose rate of ~2.6 electrons per Å 2 per s. Exposures of 16 s were dose-fractionated into 20 movie frames with a total dose of ~40 electrons per Å 2 . Defocus values in the final data set ranged from −2.0 to −3.6 μm. Image processing. Movie frames were aligned using MotionCor2 29 before subsequent processing. Contrast transfer function parameters were calculated using Gctf 30 . Particles in 140 × 140 pixels were selected automatically using Gautomatch (K. Zhang) with an inter-particle distance cutoff of 150 Å. The initial 2D references for the automated picking were created by manual picking. Picked particles were extracted and processed in RELION 2.1 31 . After three rounds of 2D classification in which 2D classes with poor structural features were removed, 30-40% of particle classes were finally selected for 3D refinement. The initial model for 3D refinement was generated ab initio using the random start-up procedure in IMAGIC-4D 32 . Overall 3D refinement yielded a 3D reconstruction with 4.5 Å resolution. To further improve the EM density map of TRIP13, a soft mask including the most rigid . Final FSC curves and sharpening of density maps was performed as described 31 . 3D classification with a global search and a sampling angular interval of 7.5° allowed the identification of apo (class 1: 20% of total) and p31-substrate-bound (80% of total) TRIP13 complexes. The TRIP13-p31-substrate class was further classified yielding the TRIP13-p31-substrate basal (class 2: 22%) and TRIP13-p31-substrate activated states (class 3: 24%) and a reconstruction (34%) with resemblance to the TRIP13-p31-substrate basal state but poorer alignment accuracy. . Model building and flexible fitting were performed in COOT 35 . TRIP13 pore loops-1 and -2 model building was performed ab initio using the crystal structure of the PAN regulatory particle 36 as an initial reference using our highest resolution maps. TRIP13 loop 111-121 was built as an idealized polyAla chain fitting to the corresponding density. The p31 comet α3-4 loop was built as polyAla chain fitting the corresponding density of a TRIP13-p31-substrate map obtained after focused classification of the N-terminal domain of TRIP13 monomer E with additional guidance from published cross-linking data restraints . Because C-MAD2 NT remained fixed, but the globular portion of p31 comet -C-MAD2 shifted by 7.6 Å (owing to the vertical movement and 60° rotation (Extended Data Fig. 9i) ), the Cα atoms of Thr12 of C-MAD2
NT and Leu13 in the globular portion of C-MAD2 were separated by 11 Å (Extended Data Fig. 9h ). Thr12 and Leu13 were reconnected by unwinding the first turn of the C-MAD2 αA helix (residues 12-17) with the coordinates refined in COOT 35 . The same procedure was applied to remodel the TRIP13-p31 comet -C-MAD2-CDC20 complex basal state 2 (post catalytic cycle 2) (Supplementary Video 2). The calculation that one helical turn is unwound per catalytic cycle is based on the following reasoning:
The axial distance between adjacent residues in an α-helix is 1.5 Å. The axial distance between adjacent residues in a β-sheet is 3.5 Å. Thus the difference in axial distance between adjacent residues in an α-helix and a β-sheet is 2 Å per residue. Stretching an α-helix by 7.6 Å by forming an extended chain requires 7.6 Å/2 Å per residue = 3.8 residues = 1.06 helical turn (assuming 3.6 residues per turn).
Structural conservation was calculated using CONSURF 38 . The interface surface area between TRIP13 and p31 comet -C-MAD2 including MAD2
NT was calculated using the PISA protein interface server 39 . Protein sequence alignment was performed using Jalview 
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Extended Data Fig. 1 | Biochemical characterization of MAD2-containing complexes with TRIP13. a, TRIP13 and p31 comet can extract O-MAD2 from MCC and APC/C-MCC regardless of APC15. Western blot showing the disassembly reactions together with the respective input material (i) of APC/C-bound MCC (APC/C-MCC), in either the absence (lanes 1-2) or presence of APC15 (lanes 3-6) and MCC alone (lanes 7-10) (experimental design is shown on top). Negative control reactions (lanes 3, 4 and 9, 10) were performed with the TRIP13(E253Q) mutant. MAD2 levels were detected with an anti-MAD2 antibody. Loading controls of APC4-STREP, APC15, CDC20, TRIP13 and BUB3 were detected with antibodies specific for STREP, APC15, CDC20, TRIP13 and BUB3, respectively. BUBR1 (lanes 7 comet -C-MAD2-CDC20 complex in the presence of ATPγS. Experiments in a-e were performed in triplicate with similar results. See Supplementary Fig. 1 for gel 
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